Recent Finacing
Recent Raise
Parthenon Therapeutics develops DDR1-targeting therapies, including lead PRTH-101, that remodel tumor extracellular matrix to overcome immune exclusion, advance a multi‑indication oncology portfolio, and collaborate with academic partners and SAB.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
